B-Cell Pathway Therapies Show Promise for Immunoglobulin A Nephropathy

Untitled

Telitacicept, a fusion protein targeting BAFF and APRIL, shows promise for IgA nephropathy in a phase 3 trial. Proteinuria ≥1.0 g/day addres

What Is IgA Nephropathy?

Learn about IgA nephropathy, its symptoms, causes, diagnosis, treatment options, lifestyle changes, prognosis, complications, and support re

<![CDATA[FDA Approves Atacicept-vymj to Reduce Proteinuria in IgA Nephropathy]]>

Nephrin autoimmunity: signal, noise, and a path to clarity

Advances in antigen discovery and autoantibody profiling have reshaped the classification of autoimmune kidney diseases, moving beyond purel

Anti-nephrin antibodies are not enriched in patients with primary and posttransplant recurrent podocytopathies

BACKGROUND Anti-nephrin autoantibodies have emerged as a putative pathogenic driver in a subset of patients with podocytopathies, including

Novartis Vanrafia: Kanadische Zulassung bei IgA-Nephropathie erteilt

ZÜRICH / LONDON (IT BOLTWISE) – Novartis meldet eine kanadische Zulassung für Vanrafia zur Behandlung der IgA-Nephropathie. Im Fokus steht d